Patents by Inventor Lawrence K. Cohen

Lawrence K. Cohen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHENYLALKYL N-HYDROXYUREAS FOR TREATING LEUKOTRIENE RELATED PATHOLOGIES
    Publication number: 20130317078
    Abstract: The method of treating patients by administering N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea for treatment of leukotriene related pathologies, and compositions for this use.
    Type: Application
    Filed: June 20, 2013
    Publication date: November 28, 2013
    Inventors: Rebecca Taub, Tilmann Brotz, John Franc, Lawrence K. Cohen, Hemantkumar H. Patel, Sanjay R. Chemburkar, David P. Sawick
  • Adeno-associated viral vector-mediated delivery of DNA to cells of the liver
    Patent number: 6936243
    Abstract: The instant invention provides methods of expressing polynucleotides in the cells of the liver comprising administering viral particles comprising a recombinant AAV vector into a mammal, preferably a human.
    Type: Grant
    Filed: May 22, 2000
    Date of Patent: August 30, 2005
    Assignees: The University of Washington, Cell Genesys, Inc.
    Inventors: Richard O. Snyder, Lawrence K. Cohen, Mark A. Kay, Olivier Danos, Arthur R. Thompson
  • Retroviral gene therapy vectors and therapeutic methods based thereon
    Patent number: 6544771
    Abstract: Retroviral vectors are disclosed which include an insertion site for genes of interest and are capable of expressing high levels of the protein derived from the genes of interest in a wide variety of transfected cell types. Also disclosed are retroviral vectors lacking a selectable marker, thus rendering them suitable for human gene therapy in the treatment of a variety of disease states without the co-expression of a marker product, such as an antibiotic. These retroviral vectors are especially suited for use in certain packaging cell lines.
    Type: Grant
    Filed: June 2, 1994
    Date of Patent: April 8, 2003
    Assignees: Cell Genesys, Inc., Whitehead Institute for Biomedical Research
    Inventors: Isabelle Rivière, Lawrence K. Cohen, Brad Guild, Lori F. Rafield, Paul Robbins, Richard C. Mulligan
  • Adeno-associated viral vector-mediated delivery of DNA to cells of the liver
    Publication number: 20020151509
    Abstract: The instant invention provides methods of expressing polynucleotides in the cells of the liver comprising administering viral particles comprising a recombinant AAV vector into a mammal, preferably a human.
    Type: Application
    Filed: May 22, 2000
    Publication date: October 17, 2002
    Inventors: Richard O. Snyder, Lawrence K. Cohen, Mark A. Kay, Oliver Danos, Arthur R. Thompson
  • Retroviral gene therapy vectors and therapeutic methods based thereon
    Patent number: 6140111
    Abstract: Retroviral vectors are disclosed which include an insertion site for genes of interest and are capable of expressing high levels of the protein derived from the genes of interest in a wide variety of transfected cell types. Also disclosed are retroviral vectors lacking a selectable marker, thus rendering them suitable for human gene therapy in the treatment of a variety of disease states without the co-expression of a marker product, such as an antibiotic. These retroviral vectors are especially suited for use in certain packaging cell lines.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 31, 2000
    Assignees: Whitehead Institute for Biomedical Research, Cell Genesys, Inc.
    Inventors: Isabelle Riviere, Lawrence K. Cohen, Brad Guild, Lori F. Rafield, Paul Robbins, Richard C. Mulligan
  • Genetic modification of endothelial cells
    Patent number: 6001350
    Abstract: Endothelial cells transduced with genetic material encoding a polypeptide or protein of interest and, optionally, a selectable marker, as well as methods for making and using the transduced endothelial cells are disclosed. Such endothelial cells are useful in improving the performance of vascular grafts and in delivering the encoded polypeptide or protein, such as an enzyme, a hormone, a receptor or a drug, to an individual.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 14, 1999
    Inventors: Richard C. Mulligan, Lawrence K. Cohen, Louis K. Birinyi, James M. Wilson
  • Genetic modification of endothelial cells
    Patent number: 5674722
    Abstract: Endothelial cells transduced with genetic material encoding a polypeptide or protein of interest and, optionally, a selectable marker, as well as methods for making and using the transduced endothelial cells are disclosed. Such endothelial cells are useful in improving the performance of vascular grafts and in delivering the encoded polypeptide or protein, such as an enzyme, a hormone, a receptor or a drug, to an individual.
    Type: Grant
    Filed: May 25, 1994
    Date of Patent: October 7, 1997
    Assignees: Somatix Therapy Corporation, Whitehead Institute For Biomedical Research, Brigham & Womens Hospital, Howard Hughes Medical Institute, New England Medical Center Hospitals
    Inventors: Richard C. Mulligan, Lawrence K. Cohen, Lori F. Rafield, Louis K. Birinyi, Allan D. Callow, James M. Wilson
  • Recombinant fowlpox virus and recombination vector
    Patent number: 5093258
    Abstract: Recombinant fowlpox virus (FPV) capable of expressing immunogenic proteins of fowl pathogens are described. The FPV express DNA of the pathogen under the direction of FPV promoters. The recombinant FPV provide live vaccines for poultry and other animals.
    Type: Grant
    Filed: August 26, 1988
    Date of Patent: March 3, 1992
    Assignee: Therion Biologics Corporation
    Inventors: Lawrence K. Cohen, Dennis L. Panicali